Thijs van der Vaart

Dr. Thijs van der Vaart

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2013 in The Lancet Neurology
Verified
Journal Article
Closed access
Thijs van der VaartThijs van der Vaart
Thijs van der Vaart
EPEllen Plasschaert
Ellen Plasschaert
ARAndré Bernard Rietman
André Bernard Rietman
MRMarleen Renard
Marleen Renard
RORianne Oostenbrink
Rianne Oostenbrink
HMHenriëtte A Moll
Henriëtte A Moll

9 July 2019 in Neurology
Verified
Journal Article
Closed access
PDF file
IOIris E. Overwater
Iris E. Overwater
ARAndré Bernard Rietman
André Bernard Rietman
SMSabine Mous
Sabine Mous
KHKaren G.C.B. Bindels-de Heus,
Karen G.C.B. Bindels-de Heus,
DRDimitris Rizopoulos
Dimitris Rizopoulos
MWMarie-Claire Y. de Wit
Marie-Claire Y. de Wit
Objective To investigate whether mammalian target of rapamycin inhibitor everolimus can improve intellectual disability, autism, and other neuropsychological deficits in children with tuberous sclerosis complex (TSC). Methods In this 12-month, randomized, double-blind, placebo-controlled trial, we attempted to enroll 60 children with TSC and IQ <80, learning disability, special schooling, or autism, aged 4–17 years, without intractable seizures to be assigned to receive everolimus or placebo. Everolimus was titrated to blood trough levels of 5–10 ng/mL. Primary outcome was full-scale IQ; secondary outcomes included autism, neuropsychological functioning, and behavioral problems. Results Thirty-two children with TSC were randomized. Intention-to-treat analysis showed no benefit of everolimus on full-scale IQ (treatment effect −5.6 IQ points, 95% confidence interval −12.3 to 1.0). No effect was found on secondary outcomes, including autism and neuropsychological functioning, and questionnaires examining behavioral problems, social functioning, communication skills, executive functioning, sleep, quality of life, and sensory processing. All patients had adverse events. Two patients on everolimus and 2 patients on placebo discontinued treatment due to adverse events. Conclusions Everolimus did not improve cognitive functioning, autism, or neuropsychological deficits in children with TSC. The use of everolimus in children with TSC with the aim of improving cognitive function and behavior should not be encouraged in this age group. Clinicaltrials.gov identifier NCT01730209. Classification of evidence This study provides Class I evidence that for children with TSC, everolimus does not improve intellectual disability, autism, behavioral problems, or other neuropsychological deficits.

12 January 2016 in Neurology
Verified
Journal Article
Closed access
PDF file
Thijs van der VaartThijs van der Vaart
Thijs van der Vaart
ARAndré Bernard Rietman
André Bernard Rietman
EPEllen Plasschaert
Ellen Plasschaert
ELEric Legius
Eric Legius
YEYpe Elgersma
Ype Elgersma
BMBadies Manai
Badies Manai
Objective: To evaluate the appropriateness of cognitive and behavioral outcome measures in clinical trials in neurofibromatosis type 1 (NF1) by analyzing the degree of deficits compared to reference groups, test-retest reliability, and how scores correlate between outcome measures. Methods: Data were analyzed from the Simvastatin for cognitive deficits and behavioral problems in patients with neurofibromatosis type 1 (NF1-SIMCODA) trial, a randomized placebo-controlled trial of simvastatin for cognitive deficits and behavioral problems in children with NF1. Outcome measures were compared with age-specific reference groups to identify domains of dysfunction. Pearson r was computed for before and after measurements within the placebo group to assess test-retest reliability. Principal component analysis was used to identify the internal structure in the outcome data. Results: Strongest mean score deviations from the reference groups were observed for full-scale intelligence (−1.1 SD), Rey Complex Figure Test delayed recall (−2.0 SD), attention problems (−1.2 SD), and social problems (−1.1 SD). Long-term test-retest reliability were excellent for Wechsler scales (r > 0.88), but poor to moderate for other neuropsychological tests (r range 0.52–0.81) and Child Behavioral Checklist subscales (r range 0.40–0.79). The correlation structure revealed 2 strong components in the outcome measures behavior and cognition, with no correlation between these components. Scores on psychosocial quality of life correlate strongly with behavioral problems and less with cognitive deficits. Conclusions: Children with NF1 show distinct deficits in multiple domains. Many outcome measures showed weak test-retest correlations over the 1-year trial period. Cognitive and behavioral outcomes are complementary. This analysis demonstrates the need to include reliable outcome measures on a variety of cognitive and behavioral domains in clinical trials for NF1.

11 July 2024 in Clinical Cancer Research
Verified
Journal Article
Closed access
Thijs van der VaartThijs van der Vaart
Thijs van der Vaart
MWMaarten M.J. Wijnenga
Maarten M.J. Wijnenga
KGKarin van Garderen
Karin van Garderen
HDHendrikus Jan Dubbink
Hendrikus Jan Dubbink
PFPim French
Pim French
MBMartin J. Van Den Bent
Martin J. Van Den Bent
Purpose: IDH-mutant glioma is classified as oligodendroglioma or astrocytoma based on 1p19q-codeletion. Whether prognostic factors are similar between these tumor types is not well understood. Experimental Design: Retrospective cohort study. Molecular characterization was performed with targeted next-generation sequencing. Tumor volumes were calculated using semiautomatic 3D segmentation on all pre- and post-operative MRI scans. Overall survival was assessed with the Cox-proportional hazards model. Results: A total of 383 patients with newly diagnosed IDH-mutant glioma were followed up for a median of 7.2 years. Grades 3 and 4 patients had significantly lower Karnofsky performance, with tumors having more contrast enhancement. Patients also received more aggressive postsurgery treatment. Postoperative tumor volume is significantly and independently associated with survival (HR, per cm3 1.19; 95% CI, 1.03–1.39) in IDH-mutant glioma. A separate analysis of oligodendroglioma and astrocytoma showed a significant association of postoperative tumor volume in astrocytoma but not in oligodendroglioma. Higher age and histologic tumor grade were associated with worse survival in patients with oligodendroglioma but not with astrocytoma. Conclusions: Our data support an initial strategy of extensive resection in patients with oligodendroglioma and astrocytoma. Other important prognostic factors differ between these tumor types, urging researchers and clinicians to keep treating these tumors as separate entities.

28 September 2024 in Developmental Medicine & Child Neurology
Verified
Journal Article
Open access
MOMyrthe J. Ottenhoff
Myrthe J. Ottenhoff
SMSabine Mous
Sabine Mous
JCJesminne Castricum
Jesminne Castricum
ARAndré Bernard Rietman
André Bernard Rietman
OOOostenbrink Oostenbrink
Oostenbrink Oostenbrink
WTWalter Taal
Walter Taal
Aim: To find proof‐of‐principle evidence for short‐term treatment with lamotrigine to improve cognitive functioning of adolescents with neurofibromatosis type 1 (NF1).Method: This was a double‐blind, parallel‐group, randomized, placebo‐controlled clinical trial (the NF1‐EXCEL trial: Examining the Cognitive and Electrophysiological benefit of Lamotrigine in Neurofibromatosis type 1; Clinicaltrials.gov identifier NCT02256124), with the aim of enrolling 60 adolescents with NF1 aged 12 to 17 years 6 months. The short‐term study intervention was 200 mg of lamotrigine taken orally for 26 weeks. The primary outcome was performance IQ tested with the Wechsler Intelligence Scale for Children, Third Edition, complemented with secondary outcomes for visuospatial learning efficacy, visual perception, visual sustained attention, fine motor coordination, attention‐deficit/hyperactivity problems, and executive functioning.Results: We screened 402 adolescents with NF1, of whom 31 (eight females) entered the study. Complete‐case analysis showed no effect of lamotrigine on either performance IQ (−0.23, 95% CI −6.90 to 6.44) or most secondary outcomes. Visual sustained attention showed a trend towards better performance in the lamotrigine group (−0.81, 95% CI −1.67 to 0.04).Interpretation: Lamotrigine did not improve cognitive functioning in adolescents with NF1. The small treatment effects make it unlikely that a larger sample size could have changed this conclusion.

3 May 2025 in Cancers
Verified
Journal Article
Open access
PDF file
JCJeroen Crouzen
Jeroen Crouzen
APAnna Petoukhova
Anna Petoukhova
MHMartijn Hakstege
Martijn Hakstege
ESElise Elisabeth Maria Wilhelmina van Schaik
Elise Elisabeth Maria Wilhelmina van Schaik
RTRishi Nandoe Tewarie
Rishi Nandoe Tewarie
JZJaap Zindler
Jaap Zindler
Background/Objectives: Neurosurgical resection is the standard treatment for large brain metastases (BMs). Postoperative stereotactic radiotherapy (SRT) is used to reduce local recurrence (LR) but does not always prevent leptomeningeal disease (LMD). This study aims to analyze patterns of tumor recurrence and to identify opportunities for the further improvement of treatment efficacy. Methods: We included 147 patients who underwent resection and SRT for BMs. The distance between the resection cavity target volume and the new tumor growth was calculated. Cox regression analyses were used to assess associations of LMD with various patient characteristics. Results: Median survival after postoperative SRT was 14 months (IQR 6–30) with a 3-year actuarial survival rate of 21%. LR occurred in 20/147 patients (14%). After total resection, LR occurred in 21% of patients after 3 years of follow-up compared to 36% after subtotal resection. Marginal LR occurred in 5/147 patients (3%). LMD was found in 21/147 patients (14%; 3-year actuarial rate, 26%), and it was found more commonly in patients with resected cerebellar metastases (23%; 3-year actuarial rate, 46%) compared to those with cerebral metastases (11%; 3-year actuarial rate 17%) (HR 2.54, 95% CI 1.07–6.04, p = 0.034). Conclusions: This study examined patterns of recurrence after postoperative radiotherapy and its implications for radiation dose, radiation field size, and treatment sequence. Local control was high after total resection. Radiation field size appeared adequate given the low incidence of marginal recurrences. Patients with cerebellar metastases showed an increased risk of LMD, underscoring the need for preventive measures, particularly preoperative SRT.